Product Description: Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
Applications: COVID-19-anti-virus
Formula: C20H20FKN6O5
Citations: Plant Biosyst. 2018, 1-8./PLoS One. 2018 Mar 30;13(3):e0195168./Bioorg Med Chem. 2019 Sep 1;27(17):3836-3845. /Clin Drug Investig. 2019 Mar;39(3):285-299. /J Infect Dis. 2022 Sep 19;jiac386./J Mol Biol. 2022 Feb 22;167507./J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692./J Virol. 2017 Jan 18;91(3). pii: e02152-16./Life Sci. 9 September 2022, 120948./Molecules. 2022 Dec 12;27(24):8829./Open Forum Infect Dis. 2024 Nov 29./PeerJ Physical Chemistry. 2019, 1:e6./Pharmaceuticals. 2023 Aug 8, 16(8), 1118./Phytomedicine. 2016 Nov 15;23(12):1383-1391. /Preprints. 2024 Apr 23./Preprints. 2024 Feb 19./SSRN. 2023 Mar 30./Virol Sin. 2023 May 10;S1995-820X(23)00054-8./Virology. 2023 Jun 21./Viruses. 2021 Jan 18;13(1):E131./Viruses. 2024 Oct 13;16(10):1607.
References: [1]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62./[2]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9/[3]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6/[4]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72./[5]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.
CAS Number: 871038-72-1
Molecular Weight: 482.51
Compound Purity: 99.96
Research Area: Infection; Cancer
Solubility: DMSO : 20.83 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 25 mg/mL (ultrasonic)
Target: HIV;HIV Integrase
Deutsch
English
